Are China Hospital Purchases Slowing? Ask Mindray
This article was originally published in PharmAsia News
Executive Summary
China’s largest medical device maker surprised everyone by posting overall second-quarter net revenue growth of 9% to $334.5 million amid challenging market conditions. It expects a further recovery in the second half, but conditions at home remain difficult.
You may also be interested in...
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.
New Graft Probes Cast Shadow Over China's Drug Pricing, Reimbursement Systems
While new legislation has pushed prescription drug pricing high up the political agenda for US lawmakers, the issue has also come into the spotlight again for Chinese regulators, which have just launched new investigations into two officials. While the two countries are taking drastically different routes to tackling pricing, the developments show compliance risks remain high in China.
Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.